Document is current
Any future updates will be listed below
-
Authors
de Souza, Juli Thomaz https://orcid.org/0000-0003-2227-7505
Minicucci, Marcos F.
Ferreira, Natália C.
Polegato, Bertha F.
Okoshi, Marina Politi
Modolo, Gabriel P.
Phillips, Bethan E.
Atherton, Philip J.
Smith, Kenneth
Wilkinson, Daniel
Gordon, Adam
Tanni, Suzana E.
Costa, Vladimir Eliodoro
Fernandes, Maria Fernanda P.
Bazan, Silméia G. Zanati
Zornoff, Leonardo A. M.
Bazan, Rodrigo
de Paiva, Sérgio A. Rupp
Azevedo, Paula Schmidt
-
Funding
Funding for this research was provided by:
National Council for Scientific and Technological Development (435047/2018-3)
- License Information
-
More Information
Article History
Received: 11 January 2023
Accepted: 13 March 2023
First Online: 22 March 2023
Declarations
:
: The study was approved by the Research Ethics Committee from Botucatu Medical School according to the Consubstantiated Opinion no. 2.421.189 (CAAE: 79844317.3.0000.5411) on December 07, 2017. This is the version 4 of June 8, 2022, of the protocol. Three amendments were sent to the Research Ethics Committee: 1 amendment was not approved (opinion number 5.307.562 of March 23, 2022) and 2 amendments were approved (opinion number 3.246.038 of April 5, 2019 and 5.456.441 of June 8, 2022).Consent will be requested for review of participants’ medical records and for the collection of blood samples to test for muscle degeneration markers by D3-methylhistidine, and biochemical dosages. Written, informed consent to participate will be obtained from all participants.All participants will have access to care at the Botucatu Clinics Hospital through the Brazil’s unified health system in case there is any event caused by the study intervention.
: Not applicable.
: The authors declare that they have no competing interests.
